BridgeBio $BBIO wins FDA approval for heart disease drug
The new drug, called Attruby, will compete against medicines from Pfizer $PFE and Alnylam Pharma $ALNY
www.statnews.com/2024/11/22/b...
The new drug, called Attruby, will compete against medicines from Pfizer $PFE and Alnylam Pharma $ALNY
www.statnews.com/2024/11/22/b...
BridgeBio wins FDA approval for heart disease drug
The FDA approved a new medicine from BridgeBio for patients with ATTR-CM, a progressive heart disease
www.statnews.com
November 23, 2024 at 2:03 PM
BridgeBio $BBIO wins FDA approval for heart disease drug
The new drug, called Attruby, will compete against medicines from Pfizer $PFE and Alnylam Pharma $ALNY
www.statnews.com/2024/11/22/b...
The new drug, called Attruby, will compete against medicines from Pfizer $PFE and Alnylam Pharma $ALNY
www.statnews.com/2024/11/22/b...
** BridgeBio Pharma's shares
BBIO
shares fall 2% to $29.39
BBIO
shares fall 2% to $29.39
September 11, 2024 at 12:41 PM
** BridgeBio Pharma's shares
BBIO
shares fall 2% to $29.39
BBIO
shares fall 2% to $29.39
BridgeBio wins FDA approval for its treatment for a progressive heart disease called ATTR-CM.
The approval was widely expected, but the FDA’s decision to include a specific mortality benefit in the drug’s prescribing label resolved a lingering controversy in BridgeBio’s favor.
The approval was widely expected, but the FDA’s decision to include a specific mortality benefit in the drug’s prescribing label resolved a lingering controversy in BridgeBio’s favor.
BridgeBio wins FDA approval for heart disease drug
The FDA approved a new medicine from BridgeBio for patients with ATTR-CM, a progressive heart disease
www.statnews.com
November 23, 2024 at 12:23 AM
BridgeBio wins FDA approval for its treatment for a progressive heart disease called ATTR-CM.
The approval was widely expected, but the FDA’s decision to include a specific mortality benefit in the drug’s prescribing label resolved a lingering controversy in BridgeBio’s favor.
The approval was widely expected, but the FDA’s decision to include a specific mortality benefit in the drug’s prescribing label resolved a lingering controversy in BridgeBio’s favor.
BridgeBio axial.substack.com/p/axial-brid...
October 26, 2023 at 11:14 PM
BridgeBio axial.substack.com/p/axial-brid...
🧪A second drug for transthyretin amyloid cardiomyopathy just got approved a week early.
At $225K/year, it's more accessible than Pfizer's $268K Vyndaqel but still far exceeds ICER's recommended $13.6K-$39K range.
Big news for the 50,000+ patients in US, but pricing debate continues.
At $225K/year, it's more accessible than Pfizer's $268K Vyndaqel but still far exceeds ICER's recommended $13.6K-$39K range.
Big news for the 50,000+ patients in US, but pricing debate continues.
BridgeBio wins FDA approval for heart disease drug
The FDA approved a new medicine from BridgeBio for patients with ATTR-CM, a progressive heart disease
www.statnews.com
November 23, 2024 at 12:40 AM
🧪A second drug for transthyretin amyloid cardiomyopathy just got approved a week early.
At $225K/year, it's more accessible than Pfizer's $268K Vyndaqel but still far exceeds ICER's recommended $13.6K-$39K range.
Big news for the 50,000+ patients in US, but pricing debate continues.
At $225K/year, it's more accessible than Pfizer's $268K Vyndaqel but still far exceeds ICER's recommended $13.6K-$39K range.
Big news for the 50,000+ patients in US, but pricing debate continues.
From the $BBIO PR:
To honor the courage of our U.S. clinical trial participants, BridgeBio will provide these patients Attruby free for life
Very cool
To honor the courage of our U.S. clinical trial participants, BridgeBio will provide these patients Attruby free for life
Very cool
BridgeBio $BBIO wins FDA approval for heart disease drug
The new drug, called Attruby, will compete against medicines from Pfizer $PFE and Alnylam Pharma $ALNY
www.statnews.com/2024/11/22/b...
The new drug, called Attruby, will compete against medicines from Pfizer $PFE and Alnylam Pharma $ALNY
www.statnews.com/2024/11/22/b...
BridgeBio wins FDA approval for heart disease drug
The FDA approved a new medicine from BridgeBio for patients with ATTR-CM, a progressive heart disease
www.statnews.com
November 23, 2024 at 5:42 PM
From the $BBIO PR:
To honor the courage of our U.S. clinical trial participants, BridgeBio will provide these patients Attruby free for life
Very cool
To honor the courage of our U.S. clinical trial participants, BridgeBio will provide these patients Attruby free for life
Very cool
New: The FDA has approved a new medicine for transthyretin amyloidosis with cardiomyopathy, boosting its developer, BridgeBio Pharma, and teeing up a battle with Pfizer (and likely soon, Alnylam), for control of a lucrative market.
biopharmadive.com/news/bridgeb...
biopharmadive.com/news/bridgeb...
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market that investors have been skeptical BridgeBio can win.
biopharmadive.com
November 23, 2024 at 12:25 AM
New: The FDA has approved a new medicine for transthyretin amyloidosis with cardiomyopathy, boosting its developer, BridgeBio Pharma, and teeing up a battle with Pfizer (and likely soon, Alnylam), for control of a lucrative market.
biopharmadive.com/news/bridgeb...
biopharmadive.com/news/bridgeb...
The Trump administration has struck new drug pricing agreements with nine biotech and pharmaceutical companies
Trump Strikes Medicaid Drug Price Deals With Nine Pharma Firms
The Trump administration has struck new drug pricing agreements with nine biotech and pharmaceutical companies including UCB SA, Bridgebio Pharma Inc. and Sun Pharmaceutical Industries Ltd.
bloom.bg
August 31, 2026 at 7:45 PM
The Trump administration has struck new drug pricing agreements with nine biotech and pharmaceutical companies
$BBIO BridgeBio halted. An approval decision for its amyloidosis therapy is likely, a week ahead of its PDUFA date.
November 22, 2024 at 9:18 PM
$BBIO BridgeBio halted. An approval decision for its amyloidosis therapy is likely, a week ahead of its PDUFA date.
BridgeBio (#$BBIO): Peer-Reviewed Study Compares Acoramidis with Tafamidis
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/bridgebio-ph...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/bridgebio-ph...
September 23, 2026 at 9:37 PM
BridgeBio (#$BBIO): Peer-Reviewed Study Compares Acoramidis with Tafamidis
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/bridgebio-ph...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/bridgebio-ph...
Success! 🧪✨
BridgeBio confirms positive Ph3 results for infigratinib: the 1st oral therapy to improve growth in achondroplasia.
From Laurence Legeai-Mallet’s 2016 lab work to real impact today. 🧬
For more info: www.linkedin.com/posts/instit...
BridgeBio confirms positive Ph3 results for infigratinib: the 1st oral therapy to improve growth in achondroplasia.
From Laurence Legeai-Mallet’s 2016 lab work to real impact today. 🧬
For more info: www.linkedin.com/posts/instit...
#institutimagine #achondroplasia #research #translationalmedicine #genetics #infigratinib #scienceforhealth | Institut Imagine
From the lab bench to Phase 3 success: A major milestone for Achondroplasia research. 🧬✨
We are proud to celebrate a pivotal moment in translational medicine. BridgeBio has announced positive topline...
www.linkedin.com
February 18, 2026 at 3:34 PM
Success! 🧪✨
BridgeBio confirms positive Ph3 results for infigratinib: the 1st oral therapy to improve growth in achondroplasia.
From Laurence Legeai-Mallet’s 2016 lab work to real impact today. 🧬
For more info: www.linkedin.com/posts/instit...
BridgeBio confirms positive Ph3 results for infigratinib: the 1st oral therapy to improve growth in achondroplasia.
From Laurence Legeai-Mallet’s 2016 lab work to real impact today. 🧬
For more info: www.linkedin.com/posts/instit...
Patrick O'Connor, CEO at Calitii, said: “Managing a complex ServiceNow environment demands a proactive approach, constant evolution and strategic insight to stay ahead of business demands. We are thrilled to deepen our relationship with BridgeBio.
www.biopharmaboardroom.com/news/1/4265/...
www.biopharmaboardroom.com/news/1/4265/...
Calitii, a Synechron Company, Secures ServiceNow Managed Services Contract With BridgeBio
Calitii, a Synechron Company, Secures ServiceNow Managed Services Contract With BridgeBio
www.biopharmaboardroom.com
January 21, 2026 at 5:49 PM
Patrick O'Connor, CEO at Calitii, said: “Managing a complex ServiceNow environment demands a proactive approach, constant evolution and strategic insight to stay ahead of business demands. We are thrilled to deepen our relationship with BridgeBio.
www.biopharmaboardroom.com/news/1/4265/...
www.biopharmaboardroom.com/news/1/4265/...
This is the way you honor participants in clinical trials. Well done, BridgeBio: “For those who participated in the clinical trials for acoramidis (Attruby), there is exceptional news: BridgeBio is offering free access to Attruby for life to these patients in the US.” arci.org/attruby-attr...
FDA Approves Attruby™ (acoramidis) for the Treatment of ATTR-CM: A New Option for Patients
The FDA’s approval of Attruby is significant for patients with ATTR-CM, providing them with another effective treatment option.
arci.org
November 23, 2024 at 7:30 PM
This is the way you honor participants in clinical trials. Well done, BridgeBio: “For those who participated in the clinical trials for acoramidis (Attruby), there is exceptional news: BridgeBio is offering free access to Attruby for life to these patients in the US.” arci.org/attruby-attr...
BridgeBio Oncology (#$BBOT): BBO-8520 Shows 53% Response Rate in 17 Patients, Monotherapy Updates in Q4
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/bridgebio-on...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/bridgebio-on...
September 23, 2026 at 6:14 PM
BridgeBio Oncology (#$BBOT): BBO-8520 Shows 53% Response Rate in 17 Patients, Monotherapy Updates in Q4
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/bridgebio-on...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/bridgebio-on...
FDA Approves BridgeBio Heart Drug, Rivaling Pfizer — FDA approves BridgeBio's heart drug, setting competition with Pfizer and Alnylam in heart disease treatment.
https://endpts.com/fda-approves-bridgebios-heart-disease-drug-setting-up-competition-with-pfizer-alnylam/
https://endpts.com/fda-approves-bridgebios-heart-disease-drug-setting-up-competition-with-pfizer-alnylam/
November 23, 2024 at 1:06 AM
FDA Approves BridgeBio Heart Drug, Rivaling Pfizer — FDA approves BridgeBio's heart drug, setting competition with Pfizer and Alnylam in heart disease treatment.
https://endpts.com/fda-approves-bridgebios-heart-disease-drug-setting-up-competition-with-pfizer-alnylam/
https://endpts.com/fda-approves-bridgebios-heart-disease-drug-setting-up-competition-with-pfizer-alnylam/
STAT+: More signs that GLP-1s may help with peripheral artery disease www.statnews.com/2026/07/01/b...
More signs that GLP-1s may help with peripheral artery disease
Anthropic will begin developing drugs, BridgeBio pockets a billion, and more biotech news from The Readout
www.statnews.com
July 2, 2026 at 2:52 AM
STAT+: More signs that GLP-1s may help with peripheral artery disease www.statnews.com/2026/07/01/b...
Next, ‘Breaking Big in Biotech’ with Neil Kumar (BridgeBio) and William Lewis (Insmed), interviewed by Adam Feuerstein.
NK: we work on genetic diseases, often not interesting for big companies.
WL: it is important to let the street know which direction you are going.
#STATBreakthrough
NK: we work on genetic diseases, often not interesting for big companies.
WL: it is important to let the street know which direction you are going.
#STATBreakthrough
May 19, 2026 at 5:35 PM
Next, ‘Breaking Big in Biotech’ with Neil Kumar (BridgeBio) and William Lewis (Insmed), interviewed by Adam Feuerstein.
NK: we work on genetic diseases, often not interesting for big companies.
WL: it is important to let the street know which direction you are going.
#STATBreakthrough
NK: we work on genetic diseases, often not interesting for big companies.
WL: it is important to let the street know which direction you are going.
#STATBreakthrough
📢 Calling women cardiologists!
Work on key topics in ATTR-CM, from early diagnosis to clinical management, with our mentorship award on Transthyretin Amyloid Cardiomyopathy, sponsored by BridgeBio.
Learn more: womenasone.org/award...
#WomenAsOneAwards #WIC #CardioSky #MedSky
Work on key topics in ATTR-CM, from early diagnosis to clinical management, with our mentorship award on Transthyretin Amyloid Cardiomyopathy, sponsored by BridgeBio.
Learn more: womenasone.org/award...
#WomenAsOneAwards #WIC #CardioSky #MedSky
February 13, 2025 at 4:30 PM
📢 Calling women cardiologists!
Work on key topics in ATTR-CM, from early diagnosis to clinical management, with our mentorship award on Transthyretin Amyloid Cardiomyopathy, sponsored by BridgeBio.
Learn more: womenasone.org/award...
#WomenAsOneAwards #WIC #CardioSky #MedSky
Work on key topics in ATTR-CM, from early diagnosis to clinical management, with our mentorship award on Transthyretin Amyloid Cardiomyopathy, sponsored by BridgeBio.
Learn more: womenasone.org/award...
#WomenAsOneAwards #WIC #CardioSky #MedSky
BridgeBio's NEJM Data Put Oral Infigratinib Closer to a Regulatory Test BridgeBio reported NEJM publication of Phase 3 infigratinib data, including...
https://www.narrowit.com/news/bridgebio-infigratinib-nejm-propel3-2026-06-28
#Bridgebio #Infigratinib #Achondroplasia #ClinicalTrials
https://www.narrowit.com/news/bridgebio-infigratinib-nejm-propel3-2026-06-28
#Bridgebio #Infigratinib #Achondroplasia #ClinicalTrials
BridgeBio NEJM PROPEL 3 Data Support Infigratinib Regulatory Plans | Narrowit.com
BridgeBio said Phase 3 PROPEL 3 data for oral infigratinib in achondroplasia were published in NEJM and support planned FDA and EMA submissions.
www.narrowit.com
June 29, 2026 at 12:18 AM
BridgeBio's NEJM Data Put Oral Infigratinib Closer to a Regulatory Test BridgeBio reported NEJM publication of Phase 3 infigratinib data, including...
https://www.narrowit.com/news/bridgebio-infigratinib-nejm-propel3-2026-06-28
#Bridgebio #Infigratinib #Achondroplasia #ClinicalTrials
https://www.narrowit.com/news/bridgebio-infigratinib-nejm-propel3-2026-06-28
#Bridgebio #Infigratinib #Achondroplasia #ClinicalTrials
3 Rare Disease Data Center Breakthroughs Spark BridgeBio Surge
https://diagnosticpath.help/bridgebio-rare-disease-data-center-breakthroughs/?utm_source=bluesky&utm_medium=social
#encalaeretnda #bridgebiostocksurge #rarediseaseclinicaldata
https://diagnosticpath.help/bridgebio-rare-disease-data-center-breakthroughs/?utm_source=bluesky&utm_medium=social
#encalaeretnda #bridgebiostocksurge #rarediseaseclinicaldata
May 27, 2026 at 8:44 AM
3 Rare Disease Data Center Breakthroughs Spark BridgeBio Surge
https://diagnosticpath.help/bridgebio-rare-disease-data-center-breakthroughs/?utm_source=bluesky&utm_medium=social
#encalaeretnda #bridgebiostocksurge #rarediseaseclinicaldata
https://diagnosticpath.help/bridgebio-rare-disease-data-center-breakthroughs/?utm_source=bluesky&utm_medium=social
#encalaeretnda #bridgebiostocksurge #rarediseaseclinicaldata
JPMorgan Rates BridgeBio Oncology Stock Overweight
JPMorgan has initiated coverage of BridgeBio Oncology (BBIO) with an overweight rating. This decision reflects confidence in the company's performan…
https://newsstocks.live/news/jpmorgan-rates-bridgebio-oncology-stock-overweight #Finance #Markets
JPMorgan has initiated coverage of BridgeBio Oncology (BBIO) with an overweight rating. This decision reflects confidence in the company's performan…
https://newsstocks.live/news/jpmorgan-rates-bridgebio-oncology-stock-overweight #Finance #Markets
July 8, 2026 at 8:01 AM
JPMorgan Rates BridgeBio Oncology Stock Overweight
JPMorgan has initiated coverage of BridgeBio Oncology (BBIO) with an overweight rating. This decision reflects confidence in the company's performan…
https://newsstocks.live/news/jpmorgan-rates-bridgebio-oncology-stock-overweight #Finance #Markets
JPMorgan has initiated coverage of BridgeBio Oncology (BBIO) with an overweight rating. This decision reflects confidence in the company's performan…
https://newsstocks.live/news/jpmorgan-rates-bridgebio-oncology-stock-overweight #Finance #Markets
Neil Kumar posting a poem from the Odyssey on LinkedIn the Friday before Phase 3 data release remains undefeated as the best biotech moment on social media
$BBIO
www.statnews.com/2024/11/22/b...
$BBIO
www.statnews.com/2024/11/22/b...
BridgeBio wins FDA approval for heart disease drug
The FDA approved a new medicine from BridgeBio for patients with ATTR-CM, a progressive heart disease
www.statnews.com
November 23, 2024 at 8:42 AM
Neil Kumar posting a poem from the Odyssey on LinkedIn the Friday before Phase 3 data release remains undefeated as the best biotech moment on social media
$BBIO
www.statnews.com/2024/11/22/b...
$BBIO
www.statnews.com/2024/11/22/b...
BridgeBio oncology spinout to go public via combination with Helix Acquisition Corp. II SPAC, to create $BBOT worth $949M. endpts.com/bridgebio-on... $BBIO
BridgeBio oncology spinout to go public via combination with SPAC from Cormorant and Bihua Chen
BridgeBio Oncology Therapeutics to go public via merger with Helix Acquisition Corp. II SPAC, led by Bihua Chen's Cormorant, with expected $600M cash and $938M equity value.
endpts.com
February 28, 2025 at 4:33 PM
BridgeBio oncology spinout to go public via combination with Helix Acquisition Corp. II SPAC, to create $BBOT worth $949M. endpts.com/bridgebio-on... $BBIO